Open Access<p>Conjunctival Melanoma: Update on Genetics, Epigenetics and Targeted Molecular and Immune-Based Therapies</p>
Author(s) -
Anastasia Gkiala,
Sotiria Palioura
Publication year - 2020
Publication title -
clinical ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 56
eISSN - 1177-5483
pISSN - 1177-5467
DOI - 10.2147/opth.s271569
Subject(s) - neuroblastoma ras viral oncogene homolog , dabrafenib , trametinib , medicine , cancer research , vemurafenib , pembrolizumab , ipilimumab , melanoma , mek inhibitor , immune checkpoint , targeted therapy , nivolumab , mapk/erk pathway , pi3k/akt/mtor pathway , immune system , immunology , immunotherapy , kinase , cancer , biology , signal transduction , kras , colorectal cancer , genetics , metastatic melanoma
To present the molecular mechanisms involved in the pathogenesis of conjunctival melanoma (CM) and review the existing literature on targeted molecular inhibitors as well as immune checkpoint inhibitors for the management of locally advanced and metastatic disease.